Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428388 · ClinicalTrials.gov registry record · NA
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
A NA study of Macular Edema and Retinal Vein Occlusion, sponsored by Barnes Retina Institute.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT01428388: Completed NA study of Macular Edema and Retinal Vein Occlusion, sponsored by Barnes Retina Institute.
NCT01428388 is a NA study of Macular Edema and Retinal Vein Occlusion that has completed, run by Barnes Retina Institute. The registered enrollment target is 150 participants, below the 169-participant average among 14 other Macular Edema trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01428388, a NA study of Macular Edema and Retinal Vein Occlusion, has completed, sponsored by Barnes Retina Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month randomized, prospective interventional trial comparing the effectiveness of ranibizumab with bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change in central retinal thickness. Secondary measures are change in visual acuity from baseline and change in angiographic properties of macular lesions from baseline after treatment.
Primary Outcome
central thickness is measured using optical coherence tomography (OCT)
Conditions Studied
Interventions
- DRUG Intravitreal injection of bevacizumab
- DRUG Intravitreal injection of ranibizumab (0.5 mg per dose)
Study Locations (1)
Missouri
- The Retina Institute - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT01428388 record still lists
NCT01428388 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 169-participant average among 14 other Macular Edema trials with a reported enrollment target (11% lower).
The record links to 2 conditions, with Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Intravitreal injection of bevacizumab is the first listed.
NCT01428388 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01428388 about?
NCT01428388 is a clinical study titled "Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion". Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been FDA-approved for the treatment of...
What is the current status of trial NCT01428388?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2011-09. Estimated completion is 2015-12.
What conditions does trial NCT01428388 study?
This clinical trial studies the following conditions: Macular Edema, Retinal Vein Occlusion.
What interventions are being tested in trial NCT01428388?
The interventions under investigation include: Intravitreal injection of bevacizumab (DRUG), Intravitreal injection of ranibizumab (0.5 mg per dose) (DRUG).
Who is sponsoring clinical trial NCT01428388?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01428388 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01428388's enrollment target sits among peer trials
150 6th of 14 higher than 9 of 14 other Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
COMPLETED · NA
-
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
RECRUITING · Phase 2
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
COMPLETED · Phase 2
-
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
COMPLETED · Phase 2
-
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia